⌘K
Loading ticker…
Celularity Inc. Class A Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Celularity Inc. Class A Common Stock (CELU) has a 3-month relative strength percentile of 5 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 30. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 14.1%, relative volume 1.40×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
5 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
CELU is in a stage 4 downtrend, week 11. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -31.2% / -56.2%.
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
CELU is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $605K notional.
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $605K |
| VXFVanguard Extended Market ETF | 0.00% | $221K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CELU Jan avg: 6.80% median: 4.23% win: 50% σ: 36.54% n: 4 2022-04-12 → 2026-05-29 | CELU Feb avg: -16.68% median: -12.07% win: 25% σ: 19.51% n: 4 2022-04-12 → 2026-05-29 | CELU Mar avg: 23.42% median: 27.11% win: 75% σ: 28.89% n: 4 2022-04-12 → 2026-05-29 | CELU Apr avg: -14.15% median: -13.87% win: 20% σ: 23.74% n: 5 2022-04-12 → 2026-05-29 | CELU May avg: 12.00% median: 8.10% win: 80% σ: 24.28% n: 5 2022-04-12 → 2026-05-29 | CELU Jun avg: -24.88% median: -18.52% win: 25% σ: 28.61% n: 4 2022-04-12 → 2026-05-29 (current) | CELU Jul avg: 8.18% median: -5.42% win: 50% σ: 40.68% n: 4 2022-04-12 → 2026-05-29 | CELU Aug avg: -3.07% median: -6.09% win: 25% σ: 17.12% n: 4 2022-04-12 → 2026-05-29 | CELU Sep avg: -24.31% median: -23.11% win: 0% σ: 19.22% n: 4 2022-04-12 → 2026-05-29 | CELU Oct avg: -14.97% median: -3.60% win: 25% σ: 25.86% n: 4 2022-04-12 → 2026-05-29 | CELU Nov avg: 5.26% median: -0.09% win: 50% σ: 31.09% n: 4 2022-04-12 → 2026-05-29 | CELU Dec avg: -12.74% median: -11.30% win: 50% σ: 27.07% n: 4 2022-04-12 → 2026-05-29 |